Cargando…

Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report

BACKGROUND: Bilateral adrenal infarction is rare and only a small number of cases have been reported so far. Adrenal infarction is usually caused by thrombophilia or a hypercoagulable state, such as antiphospholipid antibody syndrome, pregnancy, and coronavirus disease 2019. However, adrenal infarct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoshino, Yoshitomo, Manaka, Katsunori, Sato, Junichiro, Asatsuma, Yui, Horikoshi, Hirofumi, Takeuchi, Maki, Ito, Nobuaki, Fujita, Megumi, Yasunaga, Megumi, Matsuda, Kensuke, Honda, Akira, Maki, Hiroaki, Masamoto, Yosuke, Kurokawa, Mineo, Nangaku, Masaomi, Makita, Noriko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240100/ https://www.ncbi.nlm.nih.gov/pubmed/37277771 http://dx.doi.org/10.1186/s12902-023-01384-5

Ejemplares similares

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia
por: Matsuda, Kensuke, et al.
Publicado: (2022)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis
por: Aoyama, Yumi, et al.
Publicado: (2019)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Myelodysplastic/ Myeloproliferative Neoplasms-Unclassifiable (MDS/MPN-U) with Isolated Isochromosome 17q Represents a Distinct Clinico-Biologic Subset: A Multi-institutional Collaborative Study from the Bone Marrow Pathology Group
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2022)

Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies
por: Makita, Noriko, et al.
Publicado: (2022)

Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration
por: Oyama, Takashi, et al.
Publicado: (2023)

Renal biopsy cases in myeloproliferative neoplasms (MPN)
por: Fujita, Kumi, et al.
Publicado: (2013)

A case of histoplasmosis in a patient with MDS/MPN-U
por: Rastogi, Pulkit, et al.
Publicado: (2016)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
por: Bhuria, Vikas, et al.
Publicado: (2022)

Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency
por: Manaka, Katsunori, et al.
Publicado: (2021)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Casetti, I. C., et al.
Publicado: (2022)

Machine Learning–Based Prediction of Elevated PTH Levels Among the US General Population
por: Kato, Hajime, et al.
Publicado: (2022)

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021)

Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis—A Case Report
por: Bouchla, Anthi, et al.
Publicado: (2018)

Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras
por: Akutagawa, Jon, et al.
Publicado: (2016)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN)
por: Price, Gregory L., et al.
Publicado: (2014)

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

A case of MDS/MPN overlap syndrome with ring sideroblasts and thrombocytosis: Tackling the quandary of thrombosis versus hemorrhage
por: Cherniawsky, Hannah, et al.
Publicado: (2023)

The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases
por: Pizzi, Marco, et al.
Publicado: (2021)

Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia
por: Kato, Hajime, et al.
Publicado: (2023)

Incidence of ossification of the spinal ligaments in acromegaly patients
por: Hoshino, Yoshitomo, et al.
Publicado: (2022)

Bing-Neel Syndrome Successfully Treated with Tirabrutinib
por: Oyama, Takashi, et al.
Publicado: (2022)

How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey
por: Byun, Ja Min, et al.
Publicado: (2022)

Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome
por: Alshaban, Ahmed, et al.
Publicado: (2018)

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents
por: Duchmann, M, et al.
Publicado: (2017)

Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
por: Mesa, Ruben, et al.
Publicado: (2016)

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
por: Harrison, Claire N., et al.
Publicado: (2017)

Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN
por: Benlabiod, Camélia, et al.
Publicado: (2020)

PB2058: IMPACT OF COMORBIDITIES AND RESPONSE TO TREATMENT ON THE MPN SAF ASSESSMENT OF PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE SYNDROMES.
por: Mohamed, B., et al.
Publicado: (2022)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL
por: Wang, Xiaoli, et al.
Publicado: (2023)

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kpq2l0dgq25aua3ls4h1cu6ghf